Ozge Celik Buyukceran, Rahime Duygu Temelturk, Hakan Ogutlu
Klinik Psikiyatri Dergisi - 2026;29(1):68-72
The purpose of this case report was to explore the use of lorazepam, a benzodiazepine, for treating pre-meal anxiety in adolescent patients diagnosed with anorexia nervosa (AN). This study aimed to assess the effects of lorazepam on reducing anxiety, increasing food intake, and improving treatment adherence in these patients.Three cases of adolescent females with AN were presented, highlighting their clinical characteristics, treatment interventions, and outcomes. The patients received a combination of pharmacotherapy (fluoxetine, aripiprazole, and lorazepam) and psychotherapy (cognitive-behavioral therapy) as part of their treatment regimen. The dosage and duration of lorazepam administration varied for each patient based on individual needs. The introduction of lorazepam along with other medications resulted in a reduction in pre-meal anxiety and an increase in food intake among the patients. Furthermore, treatment compliance and motivation improved, leading to weight gain and resumption of menstrual cycles in all cases. Positive effects of lorazepam were observed even after discontinuation of the medication.This case report suggests that the use of lorazepam for treating pre-meal anxiety in adolescent patients with AN may be beneficial in reducing anxiety, enhancing treatment adherence, and facilitating healthy eating habits. However, due to the limited evidence available, benzodiazepines are not recommended as a first-line treatment for AN, and their usage should be cautious due to the potential risks of dependence and withdrawal. Further research is needed to evaluate the efficacy and safety of benzodiazepines, including different types and doses, for treating AN.
